Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-HIF2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARO-HIF2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARO-HIF2 | DRUG | Multiple doses of ARO-HIF2 by intravenous infusion |
Inclusion Criteria: * Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception * Willing to provide written informed consent and to comply with study requirements * Histologically confirmed locally advanced or metastatic c...
ARO-HIF2 is an investigational small molecule being developed for the treatment of advanced clear cell renal cell carcinoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ARO-HIF2 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR.
ARO-HIF2 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study of ARO-HIF2 in patients with advanced clear cell renal cell carcinoma has been completed.
ARO-HIF2 has one completed clinical trial, NCT04169711, titled 'Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma.' This Phase 1 study enrolled 26 participants in the United States and was not randomized or blinded.
ARO-HIF2 is the primary name for this investigational drug. No alternative names have been reported for this asset.